Cart
sales@molnova.com
Cyclo(L-Phe-L-Pro)
CAS No. 3705-26-8
Cyclo(L-Phe-L-Pro)( —— )
Catalog No. M31407 CAS No. 3705-26-8
Cyclo(L-Phe-L-Pro) shows broad-spectrum antibacterial and antifungal activities. Cyclo(L-Phe-L-Pro) exhibits activity against methicillin-resistant S. aureus and Enterococcus raffinosus.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 36 | In Stock |
|
| 25MG | 57 | In Stock |
|
| 50MG | 91 | In Stock |
|
| 100MG | 160 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCyclo(L-Phe-L-Pro)
-
NoteResearch use only, not for human use.
-
Brief DescriptionCyclo(L-Phe-L-Pro) shows broad-spectrum antibacterial and antifungal activities. Cyclo(L-Phe-L-Pro) exhibits activity against methicillin-resistant S. aureus and Enterococcus raffinosus.
-
DescriptionCyclo(L-Phe-L-Pro) shows broad-spectrum antibacterial and antifungal activities. Cyclo(L-Phe-L-Pro) exhibits activity against methicillin-resistant S. aureus and Enterococcus raffinosus.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number3705-26-8
-
Formula Weight244.3
-
Molecular FormulaC14H16N2O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (1023.37 mM)
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Bractoppin
Bractoppin is a drug-like inhibitor of phosphopeptide recognition by the human BRCA1 tandem (t)BRCT domain (IC50 = 0.074 μM), which selectively inhibits substrate binding with nanomolar potency in vitro.
-
Sarmazenil
Sarmazenil (Ro 15-3505) is a partial inverse agonist at the benzodiazepine receptor with pro-convulsant properties and is used in the study of chronic hepatic encephalopathy (HE).
-
IACS-52825
IACS-52825 is a selective and potent dual leucine zipper kinase (DLK) inhibitor that reverses para-mechanical aberrant pain in a CIPN mouse model for the study of neurological disorders.
